The 13th JFCR−ISCC
December 3-4, 2008
Keidanren Hall
We would like to ask your participation in the 13th Japanese Foundation for Cancer Research-International Symposium on Cancer Chemotherapy, which will be held on December 3 (Wed) and 4 (Thu), 2008, in Keidanren Hall, Otemachi, Tokyo, Japan.
Recently many international co-operative studies are ongoing for the development of new antitumor agents. We believe that such world-wide, harmonized study should become much more important in the future. Under this circumstance, we are organizing a series of international symposium entitled "International Symposium on Cancer Chemotherapy". The purpose of the symposium is to discuss recent progress in the development of new antitumor agents and future perspectives in cancer chemotherapy. The Symposia were successfully held in Tokyo in 1996-2007 with about 300-350 participants. It is hoped that the Symposium will both encourage international cooperation in cancer chemotherapy and stimulate workers in Japan.
We are looking forward to seeing you in the Symposium.
December 3, 2008 (Wednesday)
12:00-12:45
(Committee Members' Meeting)
13:00-13:10
Takashi Tsuruo (Cancer Chemotherapy Center, Tokyo)
Welcome and Introduction
I c-Met Inhibitors
Chairpersons:Mace Rothenberg (Vanderbilt-Ingram Cancer Center, Nashville)
Kiyohiko Hatake (Cancer Chemotherapy Center, Tokyo)
13:10-13:40
Donald Bottaro (National Cancer Institute, Bethesda)
HGF/Met signaling in cancer
13:40-14:10
Ravi Salgia (University of Chicago Medical Center, Chicago)
Met inhibition in cancer - especially lung cancer
14:10-14:20
Discussion
14:20-14:40
Coffee Break
Special Lecture I
Chairperson:Takashi Tsuruo (Cancer Chemotherapy Center, Tokyo)
14:40-15:20
Bruce A Chabner (MGH Cancer Center, Boston)
Title TBA
II Kinase Inhibitors
Chairpersons:Mark J Ratain (University of Chicago, Chicago)
Yoshikazu Sugimoto (Keio University, Tokyo)
15:20-15:45
Maria Koehler (GlaxoSmithKline, Philadelphia)
Predicting for maximum benefit - the tale of lapatinib
15:45-16:10
Jay Feingold (Wyeth Research, Cambridge)
Temsirolimus: New targeted therapy for renal cell carcinoma
16:10-16:35
Eisei Shin (AstraZeneca, Osaka)
VEGFR inhibitor: AZD2171
16:35-16:55
Hideo Kunitoh (National Cancer Center Hospital, Tokyo)
Randomized comparisons of gefitinib and cytotoxic chemotherapy in NSCLC patients
16:55-17:05
Discussion
IIILenalidomide and Hematologic Malignancies
Chairpersons:Ravi Salgia (University of Chicago Medical Center, Chicago)
Tomoki Naoe (Nagoya University, Nagoya)
17:05-17:25
Kaoru Tohyama (Kawasaki Medical University, Kurashiki)
Lenalidomide and myelodysplastic syndrome
17:25-17:45
Kiyohiko Hatake (Cancer Chemotherapy Center, Tokyo)
Recent trends in treatment for hematologic malignancies
17:45-17:50
Discussion
18:00-19:00
Mixer
December 4, 2008 (Thursday)
IV New Targets and New Drugs (Part 1)
Chairpersons:Donald Bottaro (National Cancer Institute, Bethesda)
Yoshiro Niitsu (Sapporo Medical University, Sapporo)
9:30-10:00
Mace Rothenberg (Vanderbilt-Ingram Cancer Center, Nashville)
New targets in the treatment of pancreatic and colorectal cancer
10:00-10:20
Mikihiko Naito (University of Tokyo, Tokyo)
Activating auto-ubiquitylation, a novel strategy to antagonize cIAP1 overexpressed in cancer
10:20-10:40
Isamu Okamoto (Kinki University School of Medicine, Osaka)
YM155, a novel small molecule survivin suppressant
10:40-10:50
Discussion
10:50-11:05
Coffee Break
V New Targets and New Drugs (Part 2)
Chairpersons:Stefan Sleijfer (Erasmus Univ. Medical Center, Rotterdam)
Michihiko Kuwano (Kyushu University, Fukuoka)
11:05-11:35
Alan Ashworth (Institute of Cancer Research, London)
PARP inihbitor and synthetic lethal approaches to cancer treatment
11:35-12:00
Axel-Rainer Hanauske (Eli Lilly, Indianapolis)
Lilly's Oncology Pipeline: small molecules, antibodies, antisense
12:00-12:10
Discussion
12:25-13:20
Luncheon Seminars
Seminar I Sponsored by GlaxoSmithKline and EFPIA
Chairperson: Kazuto Nishio (Kinki University, Osaka)
Maria Koehler (GlaxoSmithKline, Philadelphia)
Tyrosine kinase inhibitors - some challenges before they reach the right patients with cancer
Seminar II Sponsored by Eli Lilly and PhRMA
Chairperson: Toshihiko Kobayashi (PhRMA, Tokyo)
Joe Shih and Axel-Rainer Hanauske (Eli Lilly, Indianapolis)
Alimta: its discovery and clinical development
Special Lecture II
Chairperson:Saburo Sone (Tokushima University, Tokushima)
13:35-14:15
Isaiah J Fidler (Unversity of Texas MD Anderson Cancer Center, Houston)
Biology of brain metastasis and resistance to chemotherapy
VI Transcriptional Control
Chairpersons:Alan Ashworth (Institute of Cancer Research, London)
Takao Yamori (Cancer Chemotherapy Center, Tokyo)
14:15-14:35
Norio Komatsu (University of Yamanashi School of Medicine, Yamanashi)
HIF-1: a potential therapeutic target in hematologic malignancies
14:35-14:55
Minoru Yoshida (RIKEN, Wako)
Splicing factor SF3b as a novel target for cancer therapy
14:55-15:25
Yves G Pommier (National Cancer Institute, Bethesda)
Molecular pharmacology of Trabectedin (Yondelis?; ecteinascidin 743): a specific inhibitor of transcription
15:25-15:35
Discussion
15:35-15:50
Coffee Break
VIISignal Transduction and Combination Therapies
Chairpersons:Yves G Pommier (National Cancer Institute, Bethesda)
Yasuhiro Fujiwara (National Cancer Center Hospital, Tokyo)
15:50-16:20
Stefan Sleijfer (Erasmus Univ. Medical Center, Rotterdam)
Combination of cancer cell specific therapies and conventional chemotherapy
16:20-16:45
Elwyn Loh (Amgen, San Francisco)
Targeting IGF-1R for cancer therapy - AMG479
16:45-17:05
Yasuhiko Nishioka (Tokushima University, Tokushima)
E7080, multiple kinases inhibitor for malignant pleural mesothelioma
17:05-17:35
Mark J Ratain (University of Chicago, Chicago)
Blockbuster plus wonder drug: challenges in developing new drug combinations
17:35-17:45
Discussion
17:45-17:55
Bruce A Chabner (MGH Cancer Center, Boston)
Closing Remark
Access Map
Keidanren Kaikan
1-9-4, Otemachi, Chiyoda-ku, Tokyo 100-8188
TEL: +81-3-5204-1500
FAX: +81-3-5255-6255
http://www.keidanren.or.jp/english/profile/map.html
For further information
please contact:
Masako Sasaki
Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
Ariake 3-10-6, Koto-ku, Tokyo 135-8550, Japan
TEL: 81-3-3520-0111 (ex. 5413) FAX: 81-3-3570-0482
